US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% MSTR $160.01 ▲+0.00%
FinancialContent

Articles published by Legend Biotech USA Inc.

News headline image
Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Announces CEO Transition
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Corporation Announces Pricing of Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Corporation Announces Proposed Public Offering
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Announces Presentations at ASCO 2026
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Reports First Quarter 2026 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Expands Scientific Advisory Expertise to Inform Future Growth
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Host Investor Conference Call on First Quarter 2026 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN
News headline image
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
From Legend Biotech USA Inc.
Via GlobeNewswire
Tickers LEGN